Xenon Pharmaceuticals Inc (XENE) - Total Assets
Based on the latest financial reports, Xenon Pharmaceuticals Inc (XENE) holds total assets worth $981.67 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Xenon Pharmaceuticals Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Xenon Pharmaceuticals Inc - Total Assets Trend (2012–2025)
This chart illustrates how Xenon Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See XENE net asset value for net asset value and shareholders' equity analysis.
Xenon Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Xenon Pharmaceuticals Inc's total assets of $981.67 Million consist of 57.1% current assets and 42.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.3% |
| Accounts Receivable | $1.37 Million | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Xenon Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Xenon Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xenon Pharmaceuticals Inc's current assets represent 57.1% of total assets in 2025, a decrease from 95.9% in 2012.
- Cash Position: Cash and equivalents constituted 20.3% of total assets in 2025, down from 95.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Xenon Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Xenon Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Xenon Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.42 | 17.85 | 24.65 |
| Quick Ratio | 13.42 | 17.85 | 24.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $518.86 Million | $599.67 Million | $271.77 Million |
Xenon Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Xenon Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.79 |
| Latest Market Cap to Assets Ratio | 3.30 |
| Asset Growth Rate (YoY) | 23.0% |
| Total Assets | $981.67 Million |
| Market Capitalization | $3.24 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Xenon Pharmaceuticals Inc's assets at a significant premium (3.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Xenon Pharmaceuticals Inc's assets grew by 23.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Xenon Pharmaceuticals Inc (2012–2025)
The table below shows the annual total assets of Xenon Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $981.67 Million | +22.99% |
| 2024-12-31 | $798.14 Million | -17.27% |
| 2023-12-31 | $964.80 Million | +27.93% |
| 2022-12-31 | $754.15 Million | +31.84% |
| 2021-12-31 | $572.01 Million | +202.35% |
| 2020-12-31 | $189.19 Million | +28.09% |
| 2019-12-31 | $147.70 Million | +20.64% |
| 2018-12-31 | $122.43 Million | +165.45% |
| 2017-12-31 | $46.12 Million | -31.66% |
| 2016-12-31 | $67.49 Million | +5.53% |
| 2015-12-31 | $63.95 Million | -26.85% |
| 2014-12-31 | $87.42 Million | +60.44% |
| 2013-12-31 | $54.49 Million | -13.93% |
| 2012-12-31 | $63.30 Million | -- |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more